CHICAGO, April 27, 2012 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals & Biotech Industry, including Eli Lilly (NYSE: LLY), Forest Labs (NYSE: FRX), ViroPharma (Nasdaq: VPHM), Novartis (NYSE: NVS) and United Therapeutics (Nasdaq: UTHR).
A synopsis of today's Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/73859/pharma-biotech-stock-outlook-april-2012
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
We would also avoid companies like Eli Lilly (NYSE: LLY), which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. 2012 will be a challenging year for Eli Lilly, with the company losing patent exclusivity on Zyprexa in October 2011. Zyprexa sales should erode rapidly with the entry of generics. Moreover, we expect continued erosion of Gemzar sales due to genericization. Another company that is highly exposed to a patent cliff is Forest Labs (NYSE: FRX).
Another company facing generic competition is ViroPharma (Nasdaq: VPHM). Estimates are down significantly as the company's lead product, Vancocin, began facing generic competition recently. The entry of generic versions will lead to a rapid decline in branded Vancocin sales. We expect ViroPharma to remain under pressure as generic players launch their versions of the drug.
We currently have a Zacks #4 Rank on Novartis (NYSE: NVS). We expect 2012 to be a challenging year for the company given manufacturing issues, pricing headwinds, generic competition and unfavorable currency movement. The company's first quarter 2012 results were below expectations.
United Therapeutics (Nasdaq: UTHR) also carries a Zacks #4 Rank. We are not too bullish on the company's chances of gaining US approval for oral treprostinil, given the mixed data on the candidate. Moreover, the company's weak late-stage pipeline concerns us.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.